Celltrion Expects Korea Rituximab Approval Despite Biogen Action
This article was originally published in PharmAsia News
Biogen moves to halt Celltrion from selling a rituximab biosimilar in South Korea by seeking a patent scope confirmation trial as the South Korean firm gears up to launch its second biosimilar. But Celltrion doesn't expect the filing to have a large impact and foresees domestic regulatory approval this year.
Register for our free email digests: